From October 2020 it will be mandatory for all owners to microchip their horses, ponies and donkeys, or face a fine of up to £200. The new Central Equine Database will then allow local authorities and police to track down the owners of dumped horses and make sure they are punished. It will also mean lost or stolen horses will be reunited with their owners more easily.
Lord Gardiner, Animal Welfare Minister, said: "The government shares the British public’s high regard for animal welfare and it is completely unacceptable that hundreds of horses and ponies are left abandoned every year by irresponsible owners.
"That is why we have today laid new regulations in Parliament requiring horses to be microchipped. This will bolster the ability of local authorities and police to identify abandoned animals, ensuring these beautiful creatures receive the care they deserve and that those who mistreat them will face the consequences."
The BVA has welcomed the move as an important step forward for horse welfare and the integrity of the UK food chain.
British Veterinary Association Senior Vice President Gudrun Ravetz said: "We welcome this announcement to extend compulsory microchipping and believe that the measures represent an important step forward for horse welfare and the integrity of the UK food chain. The one-off cost of microchipping a horse is minimal while the animal welfare benefits in terms of being able to identify lost, stolen, abandoned or fly grazing horses, and identify horses in the face of disease outbreak, as well as the benefits to the integrity of food chain safety, are enormous.
"Universal microchipping of domesticated horses ensures that the legislation has value, the cost of implementing the new Central Equine Database (CED) is not wasted, and that food safety is protected. Together these measures will protect horses, ponies and donkeys from irresponsible owners, help loving owners to be reunited with their animals and keep the food chain free from potentially contaminated horse meat."
The regulations for the database were laid in Parliament today and, subject to parliamentary approval, will come into force on 1 October 2018.
This year’s Horse Health Week, which ran at the end of September, focused on the small things that can be done to help keep Britain’s horses happy and healthy. Equine practices were encouraged to get involved and engage with their clients throughout the week with the support of a toolkit that offered both off and online communication materials.
The toolkit included a social media campaign for practices to run called #BonVoyageBuzz. Horse owners were invited to send 'Buzz' around the (virtual) world by sharing and tagging on Facebook. By the last count, he'd reached Denmark, the U.S., Canada and Saudi Arabia. The final part of Horse Health Week was a survey that gave the views of horse owners on preventative healthcare.
MSD says the week was welcomed and supported by a number of equine vet practices which reported that the campaign generated high levels of engagement from horse owners.
Peter Young, Equine Business Manager said: "Horse Health Week was created to help practices promote their businesses and educate and promote the benefits of preventative healthcare, so we are delighted that we’ve had such a good uptake of the resources we provided this year. A number of equine practices uploaded the daily animations we created to help encourage maximimum engagement. Some also reported the animations and posters being mentioned at yard appointments so, together with equine vet practices, we’ve successfully helped raise awareness and are eduating horse owners."
If you would like to provide feedback speak to your MSD Animal Health Equine Account Manager. For further details, visit: www.healthyhorses.co.uk/horse-week.
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
Zoetis says it is working hard to resolve the situation and apologises for any convenience caused.
For more information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
Vetoquinol is introducing Equistro Kerabol Biotin, a complementary feeding stuff for horses which the company says can help maintain healthy hoof and hair growth when used daily.
Equistro Kerabol Biotin will replace Biometh Z and will be automatically supplied in its place when wholesaler stocks of Biometh Z are exhausted.
Equistro Kerabol Biotin is a complex of D-biotin, methionine and Ipaligo zinc in combination with organic selenium and Ipaligo manganese.
Available as a powder in a 3kg bucket which will last 200 days, Vetoquinol says Equistro Kerabol Biotin offers a cost-effective method of ensuring good quality hoof horn.
For more information about any Equistro product, please call 0800 169197 or speak to your local equine territory manager.
Fynadyne had been removed from sale last year after the Veterinary Medicines Directorate suspended the sale of any medicinal products containing the excipient diethanolamine (DEA), following advice to the European Medicines Agency that it could pose a risk to human health.
Finadyne 50mg/ml Solution for Injection is indicated for the alleviation of acute inflammation and pain in both cattle and pigs. It is also indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses.
The reformulated product has a shelf life of three years and is now available from wholesalers in 50ml and 100ml vials.
For further information, contact your MSD Animal Health account manager.
The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.
The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.
Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".
Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.
"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".
The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.
Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/ or by calling 0844 561 6157. The deadline for entries is Friday 27th January 2012.
Boehringer Ingelheim Vetmedica has launched Equisolon 33 mg/g oral powder, the first licensed oral prednisolone for the alleviation of inflammation associated with recurrent airway obstruction (RAO), otherwise known as heaves, in horses.
Clare Turnbull, equine brand and technical manager at Boehringer Ingelheim Vetmedica said: "Oral glucocorticoids are sometimes necessary for treating the inflammation associated with RAO. We feel it is important that when our customers need to use prednisolone for their cases, there is an equine specific product available to them that is easy to dispense and administer."
The company says Equisolon should be used in combination with environmental measures to treat RAO.
For further information on Equisolon, contact your Boehringer Ingelheim Vetmedica equine representative or call +44 (0)1344 746959.
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
Reference
Equistro has introduced Legaphyton to its range of supplements. Legaphyton has been developed to support liver function. It incorporates a new and patented complex called Siliphos®.
Siliphos® is a complex of concentrated Milk Thistle fruit extract and phospholipids, and is a source of readily available carbohydrates important for liver support.
Milk Thistle (silymarin) extract has documented virtues in liver support and is rich in flavanoligan (Silybin), while phospholipids (phosphatidylcholine) maintain healthy liver cell membrane function and repair and are crucial for essential lipoprotein transport in the liver.
“The liver is one of the most important organs and performs more often than one realises,” said Val Day, Equistro’s product manager. “Legaphyton has been introduced to give an extra boost to the horse’s liver function and help the liver fulfil its varied role.”
Equistro Legaphyton is available in 900g packs, which is sufficient for 30 days for a standard 500kg horse. Ask your Vetoquinol representative for more details or visit http://www.vetoquinol.co.uk/
.
Super early bird tickets are available till 28th May.
Rose’s programme recommendations are:
BEVA Congress programme will be embracing the overarching theme of “use it wisely or lose it forever”, chosen by BEVA President Bruce Bladon.
Bruce said: “Antibiotics is an issue which goes so far beyond equine practice and is one of the genuine threats to humanity.
"We must use these precious and finite resource wisely, or, quite reasonably, regulators will prevent us having access to them.
“But this theme resonates further, to the “social licence” which threatens the future of equine sport.
"Rather than platitudes about horse welfare, we now need to show the positive steps we can take to minimise equine injury.
"We need to be developing screening programmes and to be instrumental in safety programmes.
"Otherwise, we may lose equestrian sport forever.”
Individual super early bird BEVA members prices for a three-day pass are £539 for vets for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
Super early bird ends on 28 May 2025.
http://www.bevacongress.org
The current inventory of Equip Artervac has an expiry date of March 29, 2023 and the company is not expecting a new batch to be available until the end of September 2023.
Zoetis says it has been working with relevant organisations to implement a plan to mitigate the impact on breeders.
The Thoroughbred Breeders Association has published advice for a blood sampling scheme at: https://www.rossdales.com/news-events/tba-members-equine-vaccine-advice-regarding-disruption-to-supply-of-equip-artervac, but Zoetis highlights that the advice requires action two weeks after the most recent EVA vaccination.
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0345 300 8034
Currently fewer than one in ten veterinary students opt to go into equine practice. BEVA says it hopes that the new scheme will provide a broader base of students with an insight into the world of equine veterinary medicine and open more eyes to what’s great about being an equine vet.
Katie Roberts the President of the Association of Veterinary Students said: "This is a very exciting opportunity for students. Anecdotally, we know that some students can feel very daunted by equine practice, especially if they don’t come from a traditionally horsey background. Being able to become involved with BEVA at no cost means that they can get a true taste of the equine veterinary world in addition to their experiences on EMS, and I’m sure this will pique the interest of our members."
As part of their free membership, students will also have access to:
The initiative has been made possible with sponsorship from Baker McVeigh, CVS Group, IVC, Newmarket Equine Hospital, Rossdales, VetPartners, and XLVets.
For further information about student membership of BEVA visit: https://www.beva.org.uk/Join-BEVA/vet-student
Dechra Veterinary Products has launched Osphos, an intramuscular clodronic acid injection for the control of clinical signs associated with the bone resorptive processes of navicular syndrome in horses, the only such licensed product in the UK.
Dechra says it expects Osphos to change the way chronic lameness caused by navicular syndrome is tackled by equine vets.
According to the company, clinical trials of Osphos showed 74.7% of horses experienced improvement by at least one lameness grade at 56 days post treatment.
Dechra brand manager Emma Jennings said: "Osphos intramuscular injection contains the bisphosphonate clodronic acid which inhibits resorption in the navicular bone by binding to hydroxyapatite crystals and by direct cellular effects on osteoclasts.
"We are delighted with the results of the trials, which proved that Osphos is effective at 6 months post-treatment. We're looking forward to being able to support equine vets, vet nurses and practices by providing an intramuscular Clodronic acid injection for horses."
Dechra also says studies showed that mild transient colic was seen following just 1.6 per cent of treatments.
Osphos 60 mg/ml solution for injection for horses is available from September 2014.
WebLeC has launched a monthly online equine CPD service.
One hour live interactive sessions will take place every third Thursday at 7:30 pm. A single meeting costs £30 plus VAT, or savings can be made by taking out a flexible subscription that allows the user to choose any 12 meetings for the cost of 10 over a period of up to 24 months.
The next meeting is on 22nd September and is entitled: Colic Decision making: When to wake up the surgeon and what pain control to use. The presenter is Debra Archer form the University of Liverpool. Further details and registration links can be found at: http://www.ledstonequine.co.uk/weblec_lectures/colic.html
In addition, a recording of WebLeC's 6th meeting, which was held in partnership with BEVA and the VDS and dealt with the new guidelines and forms for pre-purchase examinations of horses, is now available to view free online at: www.bitly.com/weblecbevaPPE. Use the password: b3va to get access, and you will receive a CPD certificate if you fill in the registration form.
WebLeC has also been asked to host BEVA's online CPD and will be announcing further details of their meetings soon.
Rather than offering 'death by Powerpoint', where large numbers of delegates are invited to sit and stare at a Powerpoint screen for an hour, followed by a few questions at the end, IVC and VetSurgeon.org invited a smaller, more intimate group to come and discuss a subject on Zoom, a recording of which was then made available for everyone else to watch later.
In the case of VetSurgeon.org, the first such meeting was 'Let's Talk About Small Animal Surgery' with Alasdair Hotston-Moore: https://www.youtube.com/watch?v=p1rD3zfcUZE
Meanwhile, IVC has based its recent CPD sessions about equine emergencies on a very similar model. During the event, short case studies were presented in a format which allowed for discussion all the way through.
IVC Evidensia Equine Clinical Board Vice Chair, Mark Tabachnik said: "We decided on a reflective, case-based approach rather than the usual monologue, where so much information is thrown at you, you’re lucky to catch a couple of snippets. I wanted something that was a little more relaxed and more collaborative, like a group of colleagues chatting about the cases from their night on call over a drink or two at the pub.”
It's a format which seems to be proving popular. Chessie Greenham of Fyrnwy Vets in Shropshire said: "Interesting cases that reflected on call life, worked through in an approachable style that is easily applied to real life scenarios."
Global names in gastroenterology will be sharing the latest knowledge to help veterinary surgeons and nurses support the work of the BHS and Nottingham University’s REACT to colic campaign, which is designed to help vets and horse owners work together for colic patients.
On Friday 13th September there'll be a two-hour session chaired by Harry Carslake, a diplomate of the American College of Veterinary internal medicine (ACVIM). The session will involve five experts speaking about aspects of colic, followed by discussion and the opportunity for questions from delegates.
Natasha Jocelyn, Internal Medicine Specialist, Sussex Equine Hospital, will speak about managing the acute colic in the field: what to do when flunixin doesn’t work.
Prof. Dr. Gunther Van Loon European Veterinary Specialist in Equine Internal Medicine, Ghent University, Belgium, will discuss managing acute colic in the equine hospital.
Dr Nathan Slovis member of the American College of Internal Veterinary Medicine, Director of the McGee Medicine Department and a partner at Haygard Equine Medical Institute in Lexington, Ky will explain colic guidelines – can ‘algorithms’ help?
Prof. Dr Lutz Goehring European Veterinary Specialist in Equine Internal Medicine, Ludwig-Maximilians University Munich, will explore the question ‘is there an evidence-based approach to managing enteritis?’
David Rendle European Veterinary Specialist in Equine Internal Medicine, Rainbow Equine Hospital, North Yorkshire, will look at parasitic disease as a cause of colic and methods of management.
All BEVA Congress delegates get a certificate of attendance worth seven hours of CPD.
If you're struggling for time or torn between several lectures you can use the BEVA Congress Encore Room to play back missed lectures at your convenience. BEVA Congress is also providing day crèche for children between the ages of 0-8 years. Find out more here.
Anyone who registers for Congress before 8 May 2019 will receive significantly reduced booking fees, and BEVA members save up to £379 on their Congress passes.
Currently used by more than 200 practices and 50 universities around the world, the Equinosis Q is a diagnostic tool that can further aid the subjective lameness evaluation on all types of horses and ponies examined in the field or in hospital settings.
Christina Frigast, MRCVS, Eickemeyer Product Development Manager said: "The inertial sensors sample 20x faster than the human eye making the Equinosis Q a valuable tool to the veterinarian in the evaluation of subtle and multiple limb lameness.
"It does not interfere with the routine lameness examination as trot up on straight line, lunging and ridden evaluations can be performed on both hard and soft surfaces.
"Data is wirelessly streamed to a tablet PC and compiled into a reader-friendly report displaying the timing and severity of lameness. The effectiveness of diagnostic blocks can also be assessed with the Equinosis Q, providing the veterinarian with a percentage of improvement. In addition, comparison reports can be used to monitor rehabilitation progress."
Contact Eickemeyer to book a free demo, or for further information, visit: https://www.eickemeyer.co.uk/Diagnostics-and-Education/Anatomy-Models/Lameness-Locator-vet.html?listtype=search&searchparam=lameness
watch?v=MS6UXQSq6q0
A new study, published in the Equine Veterinary Journal (EVJ)1 has concluded that whilst horse owners are increasingly looking to vets for worm control advice and use faecal worm egg counts more frequently, they remain largely unaware of the threat of resistance to dewormers and the importance of appropriate 'targeted' dosing.
The authors of the study say that although the findings are encouraging, they indicate that further effort is needed to help owners fully understand the issue of dewormer resistance, in order to help preserve the efficacy of dewormers currently available and protect the health and welfare of their horses.
According to the British Equine Veterinary Association (BEVA), resistance of equine gastrointestinal worms to the currently available dewormers is a serious problem. The association says small redworm are the greatest concern, given their very high prevalence, potential to cause life-threatening disease and high levels of resistance. Of the three classes of anthelmintic available for their control, there is now widespread resistance to benzimidazoles (e.g. fenbendazole) and tetrahydropyrimidines (e.g. pyrantel) and reduced effectiveness of macrocyclic lactones (ivermectin and moxidectin). With no new classes of dewormer on the horizon, it's essential that efficacy of existing effective products is preserved.
The study was conducted by a UK team, led by Claire Stratford, Horse Trust Clinical Scholar in Equine Medicine at the Royal (Dick) School of Veterinary Studies, and at Moredun Research Institute. The collaborators were also supported by funding from the Elise Pilkington Trust and Horserace Betting Levy Board.
The study examined equine helminth control practices in Scotland, and was based on responses from 193 questionnaires detailing the parasite control programmes of 993 horses and ponies. The results demonstrated a lack of awareness of the significance of dewormer resistance, with 86% of respondents stating that they were unaware of the presence of resistance on their yard. The majority were relatively unconcerned about dewormer resistance, assigning a score of only 6/10 (with 10 representing highest level of concern) when asked to grade how important they perceived it to be.
On a more positive note, many respondents stated that they involved their vet in planning control strategies. Faecal worm egg count (FWEC) analysis had been performed on 62% of yards and annual treatment frequency had been reduced accordingly. The macrocyclic lactones or related combination products were the most commonly administered products; however, owners did have misconceptions regarding the specific worms they should be targeting.
Although treatments licensed for use against encysted small redworm larvae were administered by 80% of respondents, only 57% perceived that they treated for this parasite stage. Similarly, only 78% of respondents believed they were treating for tapeworm when, in fact, 90% reported using a product licensed for tapeworm treatment.
While responses indicated increased implementation of strategic (44% respondents) or targeted control (40% respondents), variations in the apparent influence of the targeted approach on treatment practices suggested some confusion over this term. Claire Stratford said: "Targeted dosing involves using regular FWEC analysis to identify an individual's egg shedding level. This is currently considered best practice, when used in conjunction with annual dosing against encysted small redworm and tapeworm. The survey indicates a need for continued knowledge transfer, together with a consistent definition of 'targeted' treatment."
Professor Celia Marr, Editor of Equine Veterinary Journal said: "It's very encouraging to see that vet advice is being increasingly sought and it seems logical that the use of FWECs is rising accordingly. But, it is equally important that the information gained from the FWECs is used wisely. Resistance to dewormers is a major health concern that is with us right now and horse owners need to be made more aware of it."
Supplies of the vaccine, which is indicated for the active immunisation for horses against equine arteritis, ran low at the end of last year when Zoetis' existing stock was due to expire without any new stock in place.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
CEVA Animal Health has confirmed its sponsorship of Stephanie Dakin, an equine veterinary PhD student at the Royal Veterinary College in London.
The four-year sponsorship, due to commence October 2008, is being run through the BBSRC Industrial CASE studentship scheme, which involves partnerships between UK-based industrial companies and eligible UK universities or research institutes, to support collaborative postgraduate research. It is the first time that CEVA, the company that recently introduced Tildren®, a treatment for equine bone disease, has undertaken such an initiative in the UK.
Stephanie is conducting her PhD on the pathogenesis and treatment of equine tendonitis. She is currently working with Professor Roger Smith, Professor of Equine Orthopaedics and Dr Jay Dudhia at the RVC, on a study to determine the efficacy of stem cells in the treatment of superficial digital flexor tendonitis in the horse.
Stephanie commented: "I am very keen to direct research in this field in order to better elucidate the mechanisms involved in tendon injury and identify therapeutic targets, such that we can improve our management and hopefully advance our ability to treat and prevent disease, thus improving the health and welfare of equine patients."
She added: "Having the opportunity to undertake this vital research, supported by the BBSRC and the industrial contribution from CEVA, is a real privilege and I hope that the findings from this study will feedback to have a direct, positive impact on clinical cases of tendonitis, in the equine and possibly the human fields."
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk
Boehringer Ingelheim Vetmedica, manufacturer of the equine pergolide Prascend, has joined forces with the British Horse Society, Redwings Horse Sanctuary and World Horse Welfare to launch the 'Talk About Cushing's (TAC)' campaign.
The initiative, which will take place throughout September and October 2011, is aimed at raising awareness of Cushing's Disease and its clinical signs, perhaps the most familiar of which is hirsutism (abnormal hair growth, or delayed shedding). Horse owners can download a £15 money-off voucher from http://www.talkaboutcushings.co.uk/ throughout the TAC initiative, which can be redeemed through their veterinary practice against blood test costs.
Boehringer says Equine Cushing's Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), is the most common endocrine disorder in older horses and ponies1 ,and that some estimates suggest over 15% of horses and ponies over 15 years of age are affected2.
Unfortunately, the initial stages of Cushing's Disease are often difficult to detect, delaying the maximum benefit of early diagnosis and intervention. Blood testing is increasingly used to detect the disease and confirm diagnosis, however many horses with clinical signs, including recurrent laminitis, still go undiagnosed.
Craig Beck, vet and equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "More than 80% of horses suffering from laminitis may have an underlying endocrine disorder, such as Cushing's Disease3.
"The TAC campaign will raise awareness of Cushing's Disease amongst both veterinary professionals and owners. It should make it easier for vets to go ahead with endocrine testing in horses and ponies with recurrent laminitis, diagnosing and treating earlier in the course of the disease."
Lee Hackett, head of welfare at the BHS, added: "Cushing's Disease is relatively common in horses yet in our experience it frequently goes undiagnosed and untreated. This is why we are fully behind the 'Talk About Cushing's' campaign - anything that raises awareness and understanding of this disease has to be of benefit to equine welfare."
Redwings' head of veterinary services Nicky Jarvis said: "At Redwings we have many horses over the age of 15, all living very happy and healthy lives. 'Old age' is not in itself a disease so when a geriatric horse loses condition or appears unwell there is always an underlying cause. If a horse continually succumbs to laminitis or loses weight, Cushing's Disease could be one explanation. However, with early diagnosis, good management and the correct treatment a horse with Cushing's can live comfortably for many years."
"Early diagnosis of Cushing's Disease can be of great benefit, other conditions such as laminitis are often associated with it and it is important that clinical signs are recognised and treated appropriately. World Horse Welfare supports the 'Talk About Cushing's' campaign as it will help people to recognise the signs and take the right action to prevent horses from suffering," concludes Tony Tyler, deputy chief executive, World Horse Welfare.
Backed by an advertising and PR campaign in the equine consumer media, Boehringer Ingelheim Vetmedica has produced a marketing pack for veterinary practices to use in the run up to, and during TAC. This includes leaflets, invoice stickers, a veterinary practice toolkit featuring an owner evening presentation, editorial copy for newsletters and websites and images to support the campaign.
For further information on TAC or Prascend, the first licensed product for the treatment of Cushing's Disease, please visit http://www.talkaboutcushings.co.uk/, contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
References
1. Donaldson et al. “Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis”. JAVMA, Vol 224, No. 7, April 1, 20042. McGowan. “Diagnostic and Management Protocols for Equine Cushings Syndrome” In Practice, November/December 20033. McGowan. “Epidemiology and Clinical Perspectives of Endocrinopathic Laminitis”, BEVA Congress 2009
BCF has announced the launch of the wireless Cuattro Slate 4 equine DR system.
BCF says the new system is available with an Automatic Exposure Detection (AED) panel, which means the plate automatically recognises the radiation from the generator, with no need for a sync cable.
Gavin Mitchell from BCF said: "This system now makes the connection from any generator to the plate and from plate to tablet now wireless. This is the new revolution for equine DR. Our rugged tablet design makes it easy to show your client your images. All you need to carry with you is the plate, tablet and generator. So much lighter to transport than previous DR systems and now also easier to move around the horse."
Sarah O'Grady from BCF added: "The powerful Cuattro software is so intuitive to use, allowing you to easily customise how your image looks. A simple three step process to take an image and just one button press to back-up images to PACS or the Cloud, makes the Slate so easy to use. If you are considering upgrading to DR or replacing your old DR system, then make sure you try out the new Slate 4."
For more information, visit www.bcftechnology.com or ask your local Account Manager for a free trial.
The procedure has already been performed in the US and Germany, where it is reported to have had a success rate of 70-80% in around 250 cases, many of which were show jumpers, eventers and dressage horses.
The team at Liphook, led by European Specialist Rachel Tucker (pictured), has now performed the procedure on six horses.
Rachel said: “Enlargement of the articular process joints of the lower neck is a relatively common finding in horses, but occasionally this can cause compression and irritation of the spinal nerves.
"The foraminotomy procedure means horses experiencing nerve pain can be made comfortable and have a good chance of returning to ridden work and a competition career.
“The surgery is minimally invasive but it is a very delicate procedure to perform because you are working very close to the spinal cord.
"Due to the location, the surgery is performed down a single portal under direct visualisation using a camera, guided by ultrasound and X-ray.
"What has been remarkable so far has been the rapid recovery of the horses, who have been home and out in a small paddock within a few days of surgery with some showing rapid signs of improved comfort and movement.
“We are very pleased with how the procedures at Liphook went.
"Our patients are continuing to recover well and we are looking forward to following their progress in the future.
https://liphookequinehospital.co.uk
Co-edited by Paddy Dixon and Vicki Nicholls, the collection comprises ten studies on physiology, disease, diagnosis and treatment techniques in equine dentistry. The editors say it gives veterinary surgeons free access to some of the most important current research in the UK.
The studies include:
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "Care of the horse’s teeth is fundamental to good health. To this end a strong working knowledge of equine dentistry should be seen as an essential cornerstone for every equine practitioner. This diverse collection has the convenience of being easily accessible, online and in one place to help keep vets fully abreast of the excellent research currently being conducted in the UK."
Vicki Nicholls, incoming president of BEVA, continued: "Advances in equine dentistry continue to gather pace and it has been a pleasure and privilege to work with Paddy Dixon collating the most current dental research that will be relevant to all equine practitioners with any level of expertise."
The equine dentistry collection is available free online at: http://bit.ly/2bBDuMW.